China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
 & Lead Plaintiff Deadline – June 13, 2017 - EconoTimes)
NEW YORK, April 26, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (NASDAQ:LBIO) and certain of its officers, on behalf of a class who purchased Lion securities between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/lbio.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Lion, through its former CEO Manish Singh, was engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting the Company to potential investors that purported to be independent from the company when, in truth, they were paid promotions; (2) Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) Singh actively participated in the promotional work for the Company and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) consequently, defendants’ public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/lbio or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Lion you have until June 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
